The PD-1 inhibitor cemiplimab (Libtayo) in combination with radiotherapy, cyclophosphamide, and GM-CSF did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.
The investigators concluded that the use of cemiplimab in combination with radiotherapy, cyclophosphamide, and GM-CSF did not show greater efficacy than what has been achieved with other PD-1 inhibitor monotherapies in patients with recurrent or metastatic HNSCC.
Babiker H, Brana, I, Mahadevan, D, et al. Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy, cyclophosphamide and GM-CSF, in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2018;29(suppl):8. Abstract 1171P.
... to read the full story